FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/10/2022
Back to search
Official data from USPTO
CANOPY Y IMMUNO-THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
04/10/2022
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
02/13/2020
Registration date
10/12/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/12/2021
Last transaction
10/12/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
IL
Examiner
CAYSIDO, REBECCA
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "CANOPY" with the letter "Y" forming a design of a tree and the wordings "IMMUNO-THERAPEUTICS" below.
Holders and representatives
Holders
CANOPY IMMUNO-THERAPEUTICS LTD.
Representatives
ROY D GROSS THE ROY GROSS LAW FIRM LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials for the treatment of autoimmune diseases and disorders; Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials for the treatment of autoimmune diseasesby eliminating specific lymphocytes' lineages or modulating the immune response using a variety of organic compounds and recombinant proteins; Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials that modulate the immune system by recombinant proteins that contain a targeting moiety and an effect or moiety to eliminate specific lymphocytes' lineages and attenuate or block antibody creation and antigen-specific immune response in autoimmune diseases for the treatment of autoimmune diseases and disorders; Pharmaceutical recombinant proteins and substances not related to pharmaceuticals and clinical trials that modulate the immune system by recombinant proteins that contain a targeting moiety and an effect or moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgGIgE or IgA and antigen-specific immune response in autoimmune diseases for the treatment of autoimmune diseases and disorders; Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials with potential immunomodulation activity to treat under and over responsiveness of the immune system for the treatment of autoimmune diseases and disorders
Publications
History of USPTO decisions and trademark events.
42 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/19/2022
FIMP
FINAL DISPOSITION PROCESSED
03/18/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
10/12/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/03/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/15/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/15/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/27/2021
PUBO
PUBLISHED FOR OPPOSITION
07/27/2021
GPNX
NOTIFICATION PROCESSED BY IB
07/24/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/07/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/24/2021
ACEC
AMENDMENT FROM APPLICANT ENTERED
06/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/25/2021
EXPI
EX PARTE APPEAL-INSTITUTED
05/25/2021
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
05/25/2021
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
05/25/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/24/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/24/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/24/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/24/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/12/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/25/2020
GNFR
FINAL REFUSAL E-MAILED
11/25/2020
CNFR
FINAL REFUSAL WRITTEN
11/25/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/04/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/28/2020
RFNT
REFUSAL PROCESSED BY IB
06/12/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/28/2020
RFRR
REFUSAL PROCESSED BY MPU
05/28/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/08/2020
CNRT
NON-FINAL ACTION WRITTEN
05/07/2020
DOCK
ASSIGNED TO EXAMINER
05/04/2020
MAFR
APPLICATION FILING RECEIPT MAILED
04/14/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/09/2020
Continuous trademark protection
Get notified about every new filing that threatens CANOPY Y IMMUNO-THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.